L-Fucose

Summary

L-Fucose (CHEMBL6067643) is a phase-3 clinical-stage small molecule; indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 4
• Chemistry: 164.16 Da · C6H12O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6067643
Name	L-Fucose
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	3034656
ChEBI	CHEBI:48204
Molecular formula	C6H12O5
Molecular weight	164.16
InChIKey	PNNNRSAQSRJVSB-KCDKBNATSA-N

SMILES: C[C@@H]([C@H]([C@H]([C@@H](C=O)O)O)O)O

IUPAC name: (2S,3R,4R,5S)-2,3,4,5-tetrahydroxyhexanal

Also known as: (-)-fucose, Avtx-803, CERC-803, Deoxygalactose-cerecor, Elfucosa, Elfucose, Fucose, l-, Fucose-cerecor, L-(-)-fucose, L-fucopyranose, L-fucose

Patent coverage: 25,989 distinct patent families (88,335 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: PA-I galactophilic lectin.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q05097	5.54	Kd	2900	nM	CHEMBL_ACT_25087212

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4).

The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	2
PHASE1/PHASE2	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05462587	PHASE3	RECRUITING	A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type II
NCT05754450	PHASE3	RECRUITING	An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II
NCT07432490	PHASE2	RECRUITING	A Phase II Study With Exploratory Outcomes of Fucose Supplementation in GLUT1 Deficiency Syndrome
NCT03354533	PHASE1/PHASE2	COMPLETED	Study of ORL-1F (L-fucose) in Patients With Leukocyte Adhesion Deficiency Type II

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).